ClinicalTrials.Veeva

Menu

Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation

University of Minnesota (UMN) logo

University of Minnesota (UMN)

Status

Enrolling

Conditions

Tinnitus

Treatments

Device: Lenire Device

Study type

Interventional

Funder types

Other

Identifiers

NCT07158034
STUDY00025649

Details and patient eligibility

About

The aim of the proposed study is to investigate the use of resting-state Electroencephalogram (EEG)-Based Brain Entropy (EBDBE) and auditory brainstem responses (ABR) as an objective measure of tinnitus improvement following the use of a bimodal stimulation device in individuals with tinnitus after six weeks of bi-modal stimulation.

Enrollment

24 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Treatment Group Inclusion Criteria:

  • 18 years and over at time of consent
  • Ability to read and understand English
  • Willing and able to provide and understand informed consent
  • Willing to commit to the full duration of the investigation
  • Subjective tinnitus
  • Tinnitus duration of greater than or equal to 3 months and less than or equal to 20 years at time of consent (only for participants in treatment group)
  • Baseline THI score from 40 to 76 (only for participants in treatment group)
  • Hearing loss condition - can hear the acoustic stimulation of the Lenire device (only for participants in treatment group)

Treatment Group Exclusion Criteria:

  • Subjective tinnitus, where pulsatility is the dominant feature (only for participants in treatment group)
  • Objective tinnitus
  • Can't hear acoustic stimulation of the Lenire device within its mid- range volume setting
  • Began wearing hearing aids within the past 3 months
  • A healthcare provider has diagnosed Meniere's disease or another disorder associated with fluctuating hearing loss.
  • History of auditory hallucinations
  • Tumor on the hearing or balance nervous systems
  • Hospitalization, or visit to a physician, for a head or neck injury, including whiplash, in the previous 12 months
  • Initiated new prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Ceased prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Changed dosage of prescription medications in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Any use of benzodiazepines or sedative hypnotics (either regularly or on demand)
  • Neurological condition that may lead to seizures or loss of consciousness (e.g., epilepsy)
  • Participant with a pacemaker or other electro-active implanted device
  • Participant previously diagnosed with psychosis or schizophrenia
  • Participants diagnosed with Burning Mouth Syndrome
  • A diagnosis of bothersome temporomandibular joint disorder (TMJ) has been rendered
  • Previous involvement in a clinical investigation for tinnitus treatment or had an implantable or surgical intervention for tinnitus
  • Inability to physically or comprehensively use the device
  • Oral piercings that cannot or will not be removed
  • Pregnancy per patient report
  • Prisoner
  • PI does not deem the candidate to be suitable for the investigation for other reasons not listed above. Rationale must be provided.

Control Group Inclusion Criteria:

  • 18 years and over at time of consent
  • Ability to read and understand English
  • Willing and able to provide and understand informed consent
  • Willing to commit to the full duration of the investigation

Control Group Exclusion Criteria:

  • Began wearing hearing aids within the past 3 months
  • Hospitalization, or visit to a physician, for a head or neck injury, including whiplash, in the previous 12 months
  • Initiated new prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Ceased prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Changed dosage of prescription medications in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Any use of benzodiazepines or sedative hypnotics (either regularly or on demand)
  • Neurological condition that may lead to seizures or loss of consciousness (e.g., epilepsy)
  • Participant previously diagnosed with psychosis or schizophrenia
  • A diagnosis of bothersome temporomandibular joint disorder (TMJ) has been rendered
  • Prisoner
  • PI does not deem the candidate to be suitable for the investigation for other reasons not listed above. Rationale must be provided.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

24 participants in 2 patient groups

Treatment Group
Experimental group
Description:
Use Lenire device for 1 hour daily
Treatment:
Device: Lenire Device
Control Group
No Intervention group
Description:
Participants in the control group will not receive the stimulation device and will not undergo any stimulation during the study.

Trial contacts and locations

1

Loading...

Central trial contact

Yezihalem Mesfin

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems